BioXcel Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- BioXcel Therapeutics's estimated annual revenue is currently $18.9M per year.
- BioXcel Therapeutics's estimated revenue per employee is $122,000
Employee Data
- BioXcel Therapeutics has 155 Employees.
- BioXcel Therapeutics grew their employee count by -37% last year.
BioXcel Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Medical Officer, Neuroscience | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | VP and CFO | Reveal Email/Phone |
5 | SVP, Chief Commercial Officer | Reveal Email/Phone |
6 | SVP, Chief Legal Officer, and Corporate Secretary | Reveal Email/Phone |
7 | SVP and Chief Research & Development Officer, OnkosXcel Therapeutics | Reveal Email/Phone |
8 | Chief Medical Officer, Neuroscience | Reveal Email/Phone |
9 | VP, Regulatory Affairs - Advertising, Promotion, Labeling & Strategy | Reveal Email/Phone |
10 | AI engineer (consultant) | Reveal Email/Phone |
BioXcel Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is BioXcel Therapeutics?
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
keywords:N/A
N/A
Total Funding
155
Number of Employees
$18.9M
Revenue (est)
-37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BioXcel Therapeutics News
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company...
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company...
Other Companies in New Haven
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $48.7M | 164 | 37% | N/A |
#2 | $15M | 166 | 4% | N/A |
#3 | $49.6M | 167 | 4% | N/A |
#4 | $15M | 170 | 4% | N/A |
#5 | $60.7M | 172 | 35% | N/A |